

Anthony Wh Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10435797/publications.pdf>

Version: 2024-02-01

18
papers

2,116
citations

516710

16
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

4192
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection". <i>Journal of Hepatology</i> , 2019, 70, 573-574.	3.7	3
2	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. <i>Hpb</i> , 2018, 20, 546-554.	0.3	36
3	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	3.7	360
4	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2017, 243, 418-430.	4.5	29
5	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	4.1	22
6	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016, 22, 7289.	3.3	138
7	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
8	<i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 3048-3056.	7.0	352
9	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed <i>MET</i> Mutation as Independent Prognostic Factor. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1292-1300.	1.1	51
10	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	3.4	9
11	Characterization of rare transforming <i>KRAS</i> mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 768-776.	3.4	61
12	Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 80.	4.4	58
13	MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. <i>Oncology Reports</i> , 2014, 31, 2071-2078.	2.6	21
14	Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. <i>Journal of Thoracic Oncology</i> , 2013, 8, 883-891.	1.1	67
15	SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3 β -catenin signaling. <i>Hepatology</i> , 2013, 57, 2287-2298.	7.3	179
16	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
17	Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. <i>Cancer Research</i> , 2011, 71, 4138-4149.	0.9	189
18	Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. <i>Clinical Cancer Research</i> , 2011, 17, 2130-2139.	7.0	224